SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form S-3 - Registration statement under Securities Act of 1933:
SEC Accession No. 0001193125-20-181162
Filing Date
2020-06-26
Accepted
2020-06-26 17:31:31
Documents
7

Document Format Files

Seq Description Document Type Size
1 FORM S-3 d926045ds3.htm S-3 265009
2 EX-5.1 d926045dex51.htm EX-5.1 13425
3 EX-10.3 d926045dex103.htm EX-10.3 102219
4 EX-23.2 d926045dex232.htm EX-23.2 1732
5 EX-23.3 d926045dex233.htm EX-23.3 1443
6 GRAPHIC g926045dsp9.jpg GRAPHIC 9837
7 GRAPHIC g926045g0625150531139.jpg GRAPHIC 7757
  Complete submission text file 0001193125-20-181162.txt   409508
Mailing Address THREE BALA PLAZA EAST. SUITE 506 BALA CYNWYD PA 19004
Business Address THREE BALA PLAZA EAST. SUITE 506 BALA CYNWYD PA 19004 844-511-9056
Larimar Therapeutics, Inc. (Filer) CIK: 0001374690 (see all company filings)

IRS No.: 203857670 | State of Incorp.: DE | Fiscal Year End: 1231
Type: S-3 | Act: 33 | File No.: 333-239510 | Film No.: 20995258
SIC: 2834 Pharmaceutical Preparations